Victoria Jordan, Value and Access Policy Director at the Association of the British Pharmaceutical Industry, argues in an article for the organisation that the framing misses a far more important part of the picture.
Industry says opportunity cost isn’t the whole story in NICE’s threshold debate
January 20, 2026 Latest NewsBioPharma
Latest Video
New Stories
-
The Dispatched Podcast 'Week in Review' - 20 February
February 20, 2026 - - Podcast -
PhRMA launches new campaign against the backdrop of a more assertive U.S.
February 19, 2026 - - Latest News -
Why does anyone accept a review outcome that simply affirms a settled order
February 19, 2026 - - Latest News -
Wesfarmers Health emerges as growth engine after delivering strong first half
February 19, 2026 - - Australian Biotech -
Telix files for European approval of brain cancer imaging candidate TLX101-Px
February 18, 2026 - - Australian Biotech -
IDT signals turnaround as revenue rises and losses narrow under strategic reset
February 18, 2026 - - Latest News -
Nyrada advances lead candidate into mid-stage trial as momentum builds across programs
February 18, 2026 - - Australian Biotech

